股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 临港实验室（核心股）官微消息，2月3日，临港实验室李昊团队与中国科学院脑智卓越创新中心刘真研 究组合作，在神经生物学顶级学术期刊《Neuron》在线发表了题为"A mesoscale optogenetics system for precise and robust stimulation of the primate cortex"的研究论文。研究团队成功建立了基于介观光遗传技 术的新型超高通道数脑机接口，攻克了对灵长类大脑皮层长期、精准、稳定刺激的技术难题，为脑机接 口和脑科学（核心股）研究领域带来了重要突破。 国信证券指出，脑机接口已进入"技术突破向商业化跃迁"的关键节点，锚定"政策+技术+场景"三重主 线。当前行业受益于十五五规划重点布局、医保赋码与医疗器械（核心股）标准落地等政策红利，叠加 Neuralink量产预期与国内临床突破的催化，全球市场规模有望迎来爆发式增长。从产品端看，侵入式产 品仍在临床试验，非侵入式产品已有部分上市，包括医疗端的脑机接口运动康复系统，以及消费端的安 睡仪等。随着芯片、电极、算法等技术的发展，法规标准的不断 ...

Group 1: Industry Overview - Brain-computer interface (BCI) technology is at a critical juncture of "technological breakthrough to commercialization," supported by policies, technology, and application scenarios [2] - The global market for BCI is expected to change due to policy benefits, external production expectations, and domestic clinical breakthroughs [2] - Invasive BCI products are still in clinical trials, while non-invasive products, such as rehabilitation systems and sleep aids, have been partially launched [2] Group 2: Technological Advancements - Advancements in chips, electrodes, and algorithms, along with improved regulatory standards, are expected to lead to intensive commercialization of BCI products in the coming years [2] - Companies like Neuralink plan to start large-scale production of BCI devices by 2026, with significant innovations in surgical procedures [2] Group 3: Competitive Landscape - The BCI industry in China is still in its early stages, with most companies being small in scale [2] - There is a notable advantage in the signal quality of invasive BCIs, while non-invasive BCIs offer high safety and ease of operation, serving as a complement to invasive types [2] Group 4: Industry Chain and Key Players - Upstream: Innovative Medical has strategically invested in Hangzhou Boling Medical Technology to enter the BCI field [3] - Midstream: Nanjing Panda is developing key technologies for multimodal human-computer interaction systems based on BCI technology [6] - Downstream: Sanbo Neuroscience has achieved breakthroughs in precise tumor removal technology and is exploring clinical applications related to brain science [8]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical sector has shown weaker performance compared to the overall market, with the biopharmaceutical sector outperforming with a 7.81% increase [1]. - The brain-computer interface (BCI) industry is experiencing significant breakthroughs and commercialization opportunities, driven by favorable policies and technological advancements [2][18]. - The AI healthcare market is projected to grow substantially, with the global market size expected to increase from USD 13.7 billion in 2022 to USD 155.3 billion by 2030, reflecting a CAGR of 35.5% [23][28]. Summary by Sections Market Performance - The overall A-share market increased by 4.09%, while the biopharmaceutical sector rose by 7.81%, indicating strong sector performance [1]. - The TTM price-to-earnings ratio for the biopharmaceutical sector is at 38.96x, which is at the 85.59th percentile of the past five years [1]. Brain-Computer Interface (BCI) - The BCI market is expected to see explosive growth due to policy support, including the "14th Five-Year Plan" and the establishment of independent billing codes for BCI devices [2][18]. - Key investment opportunities include upstream hardware suppliers, midstream companies with core patents, and downstream firms that create commercial applications in rehabilitation and industrial control [2][18]. AI in Healthcare - AI is identified as a critical application area in healthcare, with various themes such as AI in drug development, multi-omics, precision diagnostics, imaging devices, and smart healthcare being highlighted for investment [3][22]. - The launch of ChatGPTHealth by OpenAI signifies a growing trend in integrating AI with healthcare applications, enhancing patient interaction with health data [29]. Company Earnings Forecasts - Several companies in the sector have been rated as "Outperform," with projected net profits for 2024 ranging from CNY 1.4 billion to CNY 116.7 billion [4]. - Notable companies include Mindray Medical (CNY 116.7 billion), WuXi AppTec (CNY 93.5 billion), and Aier Eye Hospital (CNY 35.6 billion), all showing strong growth potential [4].

Group 1 - The National Medical Products Administration has publicly announced the formulation plan for two recommended industry standards related to brain-computer interface (BCI) invasive devices and their reliability verification methods [1] - Guosen Securities believes that the BCI industry has entered a critical phase of transitioning from technological breakthroughs to commercialization, driven by policies, technology, and application scenarios [1] - The global market for BCIs is expected to experience explosive growth due to favorable policies, including the "14th Five-Year Plan," medical insurance coding, and the implementation of medical device standards, alongside the anticipated mass production of Neuralink and breakthroughs in domestic clinical applications [1] Group 2 - Dongguan Securities reports that Elon Musk's Neuralink plans to begin large-scale production of BCI devices in 2026, with a focus on highly automated surgical procedures [2] - A significant breakthrough involves the electrode wires penetrating the dura mater without the need for removal, which is expected to enhance the BCI sector and boost the overall pharmaceutical and biotechnology market [2] - The BCI industry is identified as a future industry clearly outlined in the "14th Five-Year Plan," with ongoing policy support, suggesting investment opportunities in the BCI sector [2]

Core Insights - The article discusses the establishment of pricing for brain-computer interface (BCI) medical services in various provinces in China, highlighting the integration of these services into the healthcare system and the support from government policies [4][5][10]. Pricing and Policy Developments - The Sichuan Provincial Medical Insurance Bureau has set a maximum price for BCI services, effective from April 30, 2026, with different pricing based on hospital levels for invasive procedures [4]. - Other provinces, including Hubei, Zhejiang, and Jiangsu, have also established pricing for BCI services, with costs for invasive procedures ranging from approximately 6,000 to 6,600 yuan per procedure [5][6][7]. - The pricing structure includes insertion fees, removal fees, and adaptation fees, with some provinces incorporating non-invasive adaptation fees into insurance coverage [5][8]. Government Support and Strategic Planning - The Chinese government has outlined a strategic plan to support the BCI industry through policies that focus on planning, payment, and standards, aiming for significant advancements by 2030 [10][11]. - Multiple provinces have released action plans to promote BCI innovation and commercialization, with specific targets for clinical applications and production [11]. Technological Advancements and Market Potential - The article notes that while invasive BCI products are still in clinical trials, non-invasive products have begun to enter the market, indicating a growing application space [12]. - The industry is at a critical juncture where technological breakthroughs are expected to lead to commercial viability, supported by favorable policies and anticipated production from companies like Neuralink [15][17]. Investment Opportunities - Analysts suggest focusing on key segments of the BCI industry, including hardware suppliers, companies with core patents, and those involved in rehabilitation and industrial applications [15][16]. - Specific companies are highlighted as potential beneficiaries of the BCI market growth, including Aipeng Medical, Lepu Medical, and Xiangyu Medical, among others [16].

Core Viewpoint - The brain-computer interface (BCI) industry is at a critical juncture of transitioning from technological breakthroughs to commercial viability, driven by policies, technology, and application scenarios [1] Group 1: Industry Developments - The "2026 Brain-Computer Interface Developer Conference" is scheduled to be held in Tianjin on February 3-4, 2026, organized by the Brain-Computer Interface Industry Alliance, the Human-Machine Interaction and Co-Integration Haihe Laboratory, and Tianjin University [1] - The industry is benefiting from policy incentives such as the "14th Five-Year Plan," medical insurance coding, and the establishment of medical device standards, which are expected to catalyze significant growth in the global market [1] Group 2: Product Insights - Invasive BCI products are still undergoing clinical trials, while non-invasive products have started to enter the market, including medical rehabilitation systems and consumer sleep aids [1] - The development of chips, electrodes, and algorithms, along with the continuous improvement of regulations and standards, is expected to lead to a surge in commercialized BCI products in the coming years [1] Group 3: Investment Opportunities - The BCI industry, characterized as a high-growth sector integrating multiple cutting-edge technologies, is moving towards a critical phase of large-scale application, supported by strong policy backing and ongoing technological advancements [1] - Domestic companies have achieved parity with international leaders in certain areas, demonstrating notable performance in device miniaturization, signal transmission rates, and safety [1] - There are promising investment opportunities in the mid-to-long term across the related industry chain [1]

Core Insights - The report from Guosen Securities indicates that brain-computer interfaces (BCIs) have reached a critical juncture for transitioning from technological breakthroughs to commercial viability, anchored by the "policy + technology + scenario" framework [1] - The industry is benefiting from policy incentives such as the 14th Five-Year Plan, medical insurance coding, and the establishment of medical device standards, alongside the anticipated mass production by Neuralink and breakthroughs in domestic clinical applications, suggesting a potential explosive growth in the global market [1] Product Development - In terms of product offerings, invasive products are still in clinical trials, while non-invasive products have seen some market entry, including medical brain-computer interface systems for motor rehabilitation and consumer sleep aids [1] - With advancements in chips, electrodes, and algorithms, along with the continuous improvement of regulatory standards, it is expected that brain-computer interface products will experience intensive commercialization in the coming years [1] Investment Recommendations - The report suggests focusing on core segments of the industry chain and technological pathways, prioritizing companies with competitive advantages [1] - For upstream investments, attention should be given to hardware suppliers of EEG sensors and core chips, which will benefit from the demand surge due to equipment mass production [1] - Midstream investments should target companies with core patents and clinical resources, particularly those in the invasive sector that can benchmark against international standards and those in the non-invasive sector that can quickly implement solutions [1] - Downstream, it is advisable to track companies that form commercial closed loops in rehabilitation medicine and industrial control, while also considering synergistic opportunities in "AI + brain-computer" and "robotics + brain-computer" ecosystems [1]

Investment Rating - The investment rating for the brain-computer interface (BCI) industry is "Outperform the Market" (maintained) [1] Core Insights - The BCI industry is at a critical juncture of transitioning from technological breakthroughs to commercialization, driven by policies, technology advancements, and application scenarios. The global market is expected to experience explosive growth due to favorable policies, production expectations from companies like Neuralink, and clinical breakthroughs in China [3] - The report emphasizes focusing on core segments of the industry chain and technology routes, prioritizing companies with competitive advantages. Upstream, attention should be on hardware suppliers like EEG sensors and core chips; midstream, companies with key patents and clinical resources, especially in invasive technologies; and downstream, tracking companies that form commercial closed loops in rehabilitation and industrial control [3] Summary by Sections 1. Definition and Classification of BCI - BCI is defined as a direct communication link between brain electrical activity and external devices, used for reading or writing neural signals. It is categorized into invasive, semi-invasive, non-invasive, and interventional types [12][10] 2. Relevant Policies - The BCI industry is increasingly recognized in China, with policies like the "Implementation Opinions on Promoting the Innovation and Development of the BCI Industry" issued in July 2025, indicating a strategic focus on BCI as a national emerging industry [19][20] 3. Industry Overview - The BCI industry is transitioning from clinical trials to commercialization, with significant advancements in invasive BCI technologies led by companies like Neuralink. The report highlights the rapid development of non-invasive BCIs due to algorithm improvements and data accumulation [26][34] 4. Relevant Companies - Key players in the invasive BCI sector include Neuralink, which has conducted clinical trials and aims to decode language intentions by 2025. Other notable companies include Precision Neuroscience and Synchron, which are also making strides in the BCI field [46][49] 5. Investment Opportunities - The report identifies investment opportunities in companies that are developing BCI technologies across various applications, including rehabilitation, consumer electronics, and industrial safety. The focus is on companies that can navigate the regulatory landscape and demonstrate clinical efficacy [32][48]

Core Insights - Sanqi Interactive Entertainment has made a strategic investment of $20 million in BrainCo, aiming to explore the commercialization of brain-computer interface (BCI) technology in entertainment and XR fields [1] - The partnership is expected to enhance the application of BCI technology, which has a potential market size reaching trillions [1] - Sanqi Interactive has previously invested in the BCI sector, indicating a long-term commitment to this technology as a new generation of human-computer interaction [1][2] Investment Details - The investment in BrainCo is part of Sanqi Interactive's broader strategy to integrate technology into its core gaming business [1] - BrainCo specializes in non-invasive BCI technology and has developed various smart products, including bionic limbs and sleep aids [1] - The collaboration aims to enrich the consumer application matrix, enhancing user interaction in gaming and entertainment [1] Market Trends - The BCI technology is transitioning from laboratory research to industrial application, with significant policy support in China [2] - The market is witnessing a shift towards non-invasive BCI solutions, contrasting with the invasive approaches seen in companies like Neuralink [2] - The gaming industry is poised to leverage BCI technology to create new interactive experiences and potentially new game genres [2]

Core Insights - Company completed a $20 million investment in BrainCo, aiming to explore the commercialization of brain-computer interface (BCI) technology in entertainment and XR fields [3][4][6] - The investment is part of a strategic layout to position BCI as the "next generation human-computer interaction entry point," aligning with the company's goal of "technology empowering entertainment" [3][6][7] Investment Details - The investment in BrainCo is not the first for the company in the BCI sector; it previously invested in Huazhong Brain Control, holding a 10% stake [6] - The collaboration aims to expand the application scenarios of BCI technology, targeting a market potential that could reach trillions [3][4] Market Potential - BCI technology is expected to have a massive market space, potentially reaching a trillion-dollar scale, particularly in the entertainment and XR sectors [3][4] - The global market for BCI in the medical field is projected to reach $400 billion by 2024 [7] Technological Applications - BCI technology is anticipated to revolutionize traditional gaming interactions, allowing players to control virtual characters through brain signals, enhancing immersion and creating competitive advantages [4][6] - The technology is also being explored for applications in mental health, such as sleep and meditation, which could complement existing entertainment IPs [5][6] Competitive Landscape - The company is strategically positioned in the BCI landscape, focusing on non-invasive technologies and leveraging existing gaming IPs for integration [8][9] - The investment strategy emphasizes ecological collaboration and the ability to implement BCI technology in practical applications, differentiating the company from competitors focused solely on research [8][9]